Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study

Brief Summary

Detailed Description

The primary objective of this study is to describe the socio-demographic, clinical pathological, quality of life and treatment characteristics of patients diagnosed with cervix cancer (CC) in Brazil. Other specific objectives are: * To describe socio-demographic characteristics: age at diagnosis, education, family income, race, occupation, personal health habits - e.g.oral contraceptive use ever/never and duration; smoking never/ever/current/duration , ever drinking), sexual history, insurance coverage (private, public), institution (private, public, philanthropic), obstetric history, comorbidities, performance status, human papillomavirus vaccination or not * To describe the screening for CC: access, type, frequency and results. * To describe clinical pathological characteristics of CC: histology (adeno x squamous x adenosquamous x neuroendocrine x other) , International Federation of Gynecology and Obstetrics (FIGO) stage, pathological stage, exams for staging, date of diagnosis, site of metastasis. * To describe treatment characteristics of CC: date of surgery, type of surgery; date and duration of radiotherapy, type of radiotherapy; date, type and lines of systemic therapy (chemotherapy, monoclonal antibodies), * To describe treatment safety (grade 3-4 AEs, death due to treatment toxicity, discontinuation due to AE). In addition adverse events of special interest will be described (details on Safety section). * To describe the outcomes: follow-up exams and date of visits, persistent disease, recurrence, progression times in metastatic disease, complications (e.g. hydronephrosis/nephrostomy/ GI perforations and both GI \& genitourinary fistulae.), death due CC and death from any cause.

Primary Outcomes

Secondary Outcomes

• Number of patients with progression survival(Month 3, 6, 12, 24 and 36)
• Socio-demographic characteristics of the female population diagnosed with CC(Month 0 (beginning of the study))
• Number of patients with disease survival(Month 3, 6, 12, 24 and 36)
• Number of patients with overall survival(Month 3, 6, 12, 24 and 36)
• Number of patients with disease overall survival(Month 3, 6, 12, 24 and 36)
• Duration of treatment after the diagnosis of cervix cancer(Month 0, 3, 6,12, 24 and 36)
• Description of the method used to diagnose the brazillian female patients with cervix cancer(Month 0)
• The clinical and pathological characteristics of cervix cancer in brazilian female patients(Month 0)
• Type of treatment assessed in patients with CC(Month 0, 3, 6,12, 24 and 36)
• Type and description of the indicated treatment after the diagnosis of cervix cancer in brazilian female patients(Month 0, 3, 6,12, 24 and 36)
• Description of adverse effects of the cervix cancer treatment(Month 0, 3, 6,12, 24 and 36)
• Number of adverse effects of the cervix cancer treatment(Month 0, 3, 6,12, 24 and 36)
• Type of clinical outcomes of the patients with cervix cancer in Brazil(Month 0, 3, 6,12, 24 and 36)